Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Universite Libre de Bruxelles |
| Country | Belgium |
| Start Date | Jan 01, 2023 |
| End Date | Dec 31, 2027 |
| Duration | 1,825 days |
| Number of Grantees | 15 |
| Roles | Participant; Coordinator; Third Party; Associated Partner |
| Data Source | European Commission |
| Grant ID | 101096312 |
Alcohol-related hepatocellular carcinoma (ALD-HCC) is, in Europe, the leading cause of liver cancer (2nd most common cause of cancer-related death worldwide, affecting both men and women). ALD-HCC has a median 5-year survival rate of 15%.
Yet, the prognosis is driven by the tumour stage, with curative options providing a 5-year survival exceeding 70% for early-stage HCC (
Universite Paris 13; Institut National de la Sante Et de la Recherche Medicale; Assistance Publique Hopitaux de Paris; Finovatis; Universite Libre de Bruxelles; Fondazione Irccs Ca' Granda - Ospedale Maggiore Policlinico; Vib Vzw; Stratipath Ab; Universita Degli Studi Di Milano; Universite Paris Cite; European Association for the Studyof the Liver; European Liver Patients Association; Fundacao D. Anna de Sommer Champalimaud E Dr. Carlos Montez Champalimaud; Technische Universitaet Dresden
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant